ATLANTA - Heart surgery patients were more likely to die if given the anti-bleeding drug Trasylol, two more U.S. studies have found, renewing the claims that the drug is dangerous.
Bayer AG stopped selling the drug last fall, after a Canadian study was halted because of deaths among patients taking Trasylol.
But the new research reignited controversy over Trasylol, which was on the market for 14 years and used by doctors to treat hundreds of thousands of heart bypass patients each year.
http://www.msnbc.msn.com/id/23259981/
